Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.
Fiche publication
Date publication
septembre 2019
Journal
Clinical colorectal cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi
Tous les auteurs :
Auvray M, Tougeron D, Auclin E, Moulin V, Artru P, Hautefeuille V, Hammel P, Lecomte T, Locher C, Sickersen G, Coriat R, Lecaille C, Vernerey D, Taieb J, Pernot S
Lien Pubmed
Résumé
Although no data have been reported beyond second-line therapy, aflibercept is approved in this setting in many countries. We conducted a multicenter study to analyze the efficacy and safety of a aflibercept-chemotherapy regimen beyond second-line therapy in patients with metastatic colorectal cancer.
Mots clés
Acquired resistance, Advanced disease, Antiangiogenic, Metastatic colorectal cancer, Outcomes
Référence
Clin Colorectal Cancer. 2019 Sep 4;: